Warhound Raises $200M Seed at $1.2B Valuation to Clone Military Dogs

Warhound raised $200 million in seed funding at a $1.2 billion valuation to clone and gene-edit US military working dogs — animals that do not exist yet. The Texas startup came out of stealth on October 22, TechCrunch reported.

The problem it's targeting is concrete. By Warhound's own figures, fewer than half of the working dogs the US military buys ever qualify for service, and more than 80% of them come from Europe. The company says cloning can fix both the supply dependence and the failure rate.

The idea came from Ben Lamm, co-founder and CEO of Colossal Biosciences, and Palmer Luckey, founder of Anduril Industries. "Every day, we ask dogs to put their lives on the line to protect ours," Lamm said in the launch announcement.

Who is backing Warhound?

Sequoia Capital, In-Q-Tel, ARK Invest, Franklin Templeton, 8VC, and Lux Capital are among the backers, alongside USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, and Builders VC. The company has not named a lead investor. In-Q-Tel is a venture firm funded by the CIA and other US intelligence agencies.

The cap table reads like the overlap of two portfolios. Five of the 12 named backers — In-Q-Tel, USIT, Breyer Capital, Bob Nelsen, and Builders VC — previously backed Colossal. Two more, 8VC and Lux Capital, back Anduril, and Lux closed a $1.5 billion fund in January.

"Palmer, Ben and the Warhound team are exceptional. Sequoia is proud to back them," said Shaun Maguire, a partner at Sequoia Capital.

How will the cloned dogs be made?

Colossal takes cell lines from top-performing Belgian Malinois and German Shepherds and stores them in a biobank. Its scientists then edit the genes, adding performance traits and removing variants linked to problems such as hip dysplasia and muscle atrophy, Lamm told TechCrunch. Viagen, another Colossal-owned company, will handle the cloning.

Anduril supplies protective vests, eye protection, and software that tell handlers more about what's happening around the dog. Lamm said the equipment goes on the dog, not in it.

"Colossal has spent years pioneering breakthroughs in genetics, cloning, and animal biology, and now we're applying that science to give these dogs the best possible chance at a long, healthy life and a successful mission. If we're going to ask man's best friend to protect America, we owe it to them to use every tool at our disposal to protect them, too," Lamm said.

"Man's best friend deserves man's best tech," Luckey said. He holds no equity in Warhound, Lamm said; Colossal owns the stake and licenses its technology to the company.

The first batch of dogs is about to be cloned and incubated, with births expected in early 2027 and service within two years, Lamm told TechCrunch. Warhound has not set a price. It expects to sell to the Department of Defense, military service groups, police forces, and first responders.

Who runs the company?

David Spirk, a former US Marine, runs Warhound as chief executive. He was the Pentagon's first chief data officer, held senior intelligence roles at US Special Operations Command, and joined Palantir Technologies as a senior counsellor in 2022. A February 2025 board announcement from drone maker PDW also listed him as an advisory board member at Colossal.

"Our long-term goal is simple: healthier dogs, better-prepared teams, and more service members and first responders coming home safely," Spirk said. "My focus is building a team that can turn scientific advances into capabilities that work in the field."

How big is the defence funding boom?

Warhound's seed round is small next to what other defence startups are raising. According to S&P Global Market Intelligence, defence-focused startups raised $29 billion through funding rounds in 2025, nearly triple the 2020 total.

Shield AI raised $2 billion on March 26: a $1.5 billion Series G at a $12.7 billion valuation, plus $500 million of preferred equity from Blackstone funds. Anduril raised a $5 billion Series H at a $61 billion valuation on May 13, led by Thrive Capital and Andreessen Horowitz. Since October 13 it has let employees sell shares at a price implying about $90 billion, TFN reported.

Europe sits on both sides of this story. It supplies more than 80% of US military working dogs, the company says, and it's producing Anduril rivals: Tekever reached a $6.4 billion valuation in September with a $580 million round, and Destinus was seeking €200 million at a €5 billion valuation, TFN reported in May.

Can the welfare objections be answered?

Warhound has lined up outside voices early. American Humane Society will guide welfare standards and training certification, and retired dogs are meant to enter its Military Working Dog Reunification Program, Lamm told TechCrunch.

"Working dogs are extraordinary animals whose courage and loyalty save lives," said Dr. Robin Ganzert, President and CEO of American Humane Society. "We owe these dogs a commitment to their well-being that matches their service to us."

"Advances in biotechnology bring both opportunity and responsibility," said Alta Charo, professor of law and bioethics at the University of Wisconsin–Madison. "What I find promising about Warhound is the opportunity to improve working dogs' health and welfare while supporting their lifesaving work."

On civilian safety, Lamm said the dogs will be trained like any military working dog and managed by whoever buys them. He said the company has briefed many government groups.

Colossal itself raised a $200 million Series C at a $10.2 billion valuation in January 2025 and has raised just over $555 million in total, Lamm told Pulse 2.0 in October 2025.

The verdict on Warhound's valuation will arrive on a schedule. If the first cloned litter lands in early 2027 and far more than half of those dogs pass training, the $1.2 billion will have been earned. If the pass rate looks like today's, the company will have spent serious defence money relearning how hard it is to train a dog.